Degroof Petercam Asset Management Alnylam Pharmaceuticals, Inc. Transaction History
Degroof Petercam Asset Management
- $8.32 Trillion
- Q1 2024
A detailed history of Degroof Petercam Asset Management transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Degroof Petercam Asset Management holds 2,520 shares of ALNY stock, worth $646,254. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,520
Previous 2,520
-0.0%
Holding current value
$646,254
Previous $482 Million
21.92%
% of portfolio
0.0%
Previous 0.01%
Shares
1 transactions
Others Institutions Holding ALNY
# of Institutions
673Shares Held
112MCall Options Held
943KPut Options Held
922K-
Capital World Investors Los Angeles, CA16.6MShares$4.26 Billion0.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.7MShares$3.27 Billion0.05% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.45 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA6.97MShares$1.79 Billion0.35% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.38MShares$1.12 Billion0.64% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $31.6B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...